For an adult with type 2 diabetes mellitus who requires substantial weight loss, what are the recommended use, dosing, regulatory approval status, and contraindications of tirzepatide compared with cagrilintide, and what alternative Targeting the weight within: obesity pharmacotherapy in cardiovascular disease Medicine Today Presented at the ADA 85th Scientific Sessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant Unveiling the Therapeutic Potential of the Second Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults